Recent Updates
Recently added Catalysts

MK633

Phase 2

Chronic Obstructive Pulmonary Disease (COPD) | Small molecule | Respiratory |Merck & Company, Inc.|Last Updated: Sep 3, 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment266

FDA Designations

No designations recorded

Clinical trial landscape

MK633 · 1 trial · 1 indication

Phase 2 1
NCT00418613A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED266 Analytics
PHASE2COMPLETED
A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)
Chronic Obstructive Pulmonary Disease (COPD)
NCT00418613266
Unlock trial analytics

Study Endpoints

Primary Endpoints

Pulmonary function test data
Measured over 12 weeks

Secondary Endpoints

Overall daytime symptoms score, total daily beta agonist use, and Chronic Respiratory Disease Questionnaire (CRQ) score
Measured over 12 weeks of treatment
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1EXPERIMENTALMK0633
2PLACEBO_COMPARATORPlacebo

Interventions

NameTypeDescription
MK633DRUGMK0633 100mg capsules qd for a 12-wk treatment period.
Comparator: Placebo (unspecified)DRUGMK0633 100mg Pbo capsules for a 12-wk treatment period
Unlock Study Design Details

Eligibility Criteria

Age Range40 Years to 75 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Documented COPD defined by clinical history and spirometry, with symptoms including dyspnea, wheezing, chest tightness, cough, sputum production, or nocturnal awakening * Male or postmenopausal females 40 -75 years of age Exclusion Criteria: * Impaired renal function * Histo...

Unlock Eligibility Criteria

Frequently asked questions about MK633

What is MK633 used for in COPD?

MK633 is an investigational small molecule being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is currently in Phase 2 clinical development and is not approved by the FDA. The drug is being evaluated for its potential to treat patients with COPD.

Who makes MK633?

MK633 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with COPD.

What phase is MK633 in?

MK633 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD), with one completed Phase 2 trial.

What clinical trials is MK633 in?

MK633 has one completed clinical trial, identified as NCT00418613. This Phase 2 study, titled "A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)", enrolled 266 participants aged 40 years and older. The trial was randomized, double-blind, and placebo-controlled.

Is MK633 the same as MK0633?

Yes, MK633 is also known as MK0633. The clinical trial NCT00418613 refers to the drug as MK0633, indicating that both names are used interchangeably for the same investigational compound being developed for Chronic Obstructive Pulmonary Disease (COPD).